Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Sell

Exponential Moving Average

Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Sell

Wall Street Data Solutions Rating

Neutral

B

Longboard Pharmaceuticals, Inc. Common Stock (LBPH)

Pharmaceutical Preparations

https://www.longboardpharma.com

Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.

4275 EXECUTIVE SQUARE, SUITE 950
LA JOLLA, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/12/2021

Market Cap

1,354,092,222

Shares Outstanding

23,860,000

Weighted SO

35,357,249

Total Employees

N/A

Upcoming Earnings

11/07/2024

Similar Tickers

MOLN --.--%

MNOV --.--%

ANEB --.--%

CSBR --.--%

CYT --.--%

HOWL --.--%

EWTX --.--%

DBTX --.--%

CELC --.--%

Beta

1.2610

Last Div

0.0000

Range

3.6-40.48

Chg

-0.1100

Avg Vol

576504

Mkt Cap

1354092222

Exch

NASDAQ

Country

US

Phone

619 592 9775

DCF Diff

34.2503

DCF

0.6097

Div Yield

0.0000

P/S

169261.5278

EV Multiple

-18.4259

P/FV

4.5941

Div Yield %

0.0000

P/E

-20.9062

PEG

-4.3729

Payout

0.0000

Current Ratio

20.9544

Quick Ratio

20.9544

Cash Ratio

0.9906

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

180675.0000

CCC

-180675.0000

Gross Margin

0.3750

Op Margin

-9113.5000

Pretax Margin

-8092.2500

Net Margin

-8092.2500

Eff Tax Rate

0.0095

ROA

-0.2069

ROE

-0.3693

ROCE

-0.2445

NI/EBT

1.0000

EBT/EBIT

0.8879

EBIT/Rev

-9113.5000

Debt Ratio

0.0123

D/E

0.0131

LT Debt/Cap

0.0120

Total Debt/Cap

0.0129

Int Coverage

-144.0870

CF/Debt

-15.1800

Equity Multi

1.0621

Rec Turnover

0.0000

Pay Turnover

0.0020

Inv Turnover

0.0000

FA Turnover

0.0021

Asset Turnover

0.0000

OCF/Share

-1.5078

FCF/Share

-1.5078

Cash/Share

7.8413

OCF/Sales

-7328.1250

FCF/OCF

1.0000

CF Coverage

-15.1800

ST Coverage

-199.4048

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

4.5941

P/B

4.5941

P/S

169261.5278

P/E

-20.9062

P/FCF

-23.0975

P/OCF

-23.0861

P/CF

-23.0861

PEG

-4.3729

P/S

169261.5278

EV Multiple

-18.4259

P/FV

4.5941

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Nov 20, 23:06 SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of MARX, BRKH, MNTX and LPBH Benzinga Oct 20, 21:22 Oklo, CleanSpark And Wolfspeed Are Among Top 7 Mid Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio? The Motley Fool Jan 17, 05:51 Forget the "Magnificent Seven" -- This Stock Has Nearly Quadrupled in 2024, and Wall Street Thinks It Can Go a Lot Higher Benzinga Jan 16, 12:00 Cantor Fitzgerald Maintains Overweight Rating for Longboard Pharmaceuticals: Here's What You Need To Know MarketWatch Jan 06, 05:58 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks Benzinga Jan 02, 13:55 There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target MarketWatch Jan 02, 12:26 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks MarketWatch Jan 02, 12:26 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks Benzinga Oct 24, 15:00 The Latest Analyst Ratings for Longboard Pharmaceuticals

Revenue Product Segmentation